Page last updated: 2024-12-11

alloxanthin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

alloxanthin: do not confuse with alloxanthine which is a pyrazolopyrimidine; do not confuse with alloxantin which is a barbiturate; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6443740
CHEBI ID181749
SCHEMBL ID39153
MeSH IDM0049048

Synonyms (26)

Synonym
CHEBI:181749
alloxanthin/tetradehydrozeaxanthin/(cynthiaxanthin)/(pectenoxanthin)
28380-31-6
(1r)-4-[(3e,5e,7e,9e,11e,13e,15e)-18-[(4r)-4-hydroxy-2,6,6-trimethylcyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-3,5,7,9,11,13,15-heptaen-1,17-diynyl]-3,5,5-trimethylcyclohex-3-en-1-ol
alloxanthin/ tetradehydrozeaxanthin / (cynthiaxanthin)/ (pectenoxanthin)
LMPR01070053
alloxanthin
7,7',8,8'-tetrahydro-beta,beta-carotene-3,3'-diolbeta,beta-carotene-3,3'-diol, 7,7',8,8'-tetradehydro-, (3r,3'r)-
g15l7oo8sq ,
unii-g15l7oo8sq
beta,beta-carotene-3,3'-diol, 7,7',8,8'-tetradehydro-, (3r,3'r)-
SCHEMBL39153
.beta.-carotene-3,3'-diol, 7,7',8,8'-tetradehydro-, (3r,3'r)-all-trans-
cryptomonaxanthin
tetradehydrozeaxanthin
all-trans-alloxanthin
(1r)-4-((3e,5e,7e,9e,11e,13e,15e)-18-((4r)-4-hydroxy-2,6,6-trimethylcyclohexen-1-yl)-3,7,12,16-tetramethyloctadeca-3,5,7,9,11,13,15-heptaen-1,17-diynyl)-3,5,5-trimethylcyclohex-3-en-1-ol
(1r,1'r)-4,4'-((3e,5e,7e,9e,11e,13e,15e)-3,7,12,16-tetramethyloctadeca-3,5,7,9,11,13,15-heptaen-1,17-diyne-1,18-diyl)bis(3,5,5-trimethylcyclohex-3-en-1-ol)
(3r,3'r)-alloxanthin
(3r,3'r)-7,7',8,8'-tetradehydro-.beta.,.beta.-carotene-3,3'-diol
alloxanthin (constituent of spirulina) [dsc]
cynthiaxanthin
.beta.,.beta.-carotene-3,3'-diol, 7,7',8,8'-tetradehydro-, (3r,3'r)-
Q27278551
DTXSID801321358
(1~{r})-3,5,5-trimethyl-4-[(3~{e},5~{e},7~{e},9~{e},11~{e},13~{e},15~{e})-3,7,12,16-tetramethyl-18-[(4~{r})-2,6,6-trimethyl-4-oxidanyl-cyclohexen-1-yl]octadeca-3,5,7,9,11,13,15-heptaen-1,17-diynyl]cyclohex-3-en-1-ol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diterpenoidAny terpenoid derived from a diterpene. The term includes compounds in which the C20 skeleton of the parent diterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (10.00)18.7374
1990's0 (0.00)18.2507
2000's4 (40.00)29.6817
2010's4 (40.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.70 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]